Development of safe and efficient small interfering RNA (siRNA) delivery systems still remains elusive in clinical applications of siRNA for cancer treatment.[1] An ideal siRNA delivery system is required to be stable in the blood for preferential tumor targeting and overcome a variety of physiological barriers followed by efficient intracellular siRNA release for enhanced therapeutic efficacy.